Editorial: Baseline Drug Clearance Predicts Outcomes in Children With Inflammatory Bowel Disease Treated With Vedolizumab

Courtney Bartel¹, Phillip Minar^{1

2}

Affiliations

¹ Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
² University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

Editorial

Courtney Bartel et al. Aliment Pharmacol Ther. 2025 Mar.

. 2025 Mar;61(6):1063-1064.

doi: 10.1111/apt.18519. Epub 2025 Jan 31.

Courtney Bartel¹, Phillip Minar^{1

2}

¹ Department of Pediatrics, Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center, Cincinnati, Ohio, USA.
² University of Cincinnati College of Medicine, Cincinnati, Ohio, USA.

No abstract available

References

1. A. Hemperly, W. J. Sandborn, and C. N. Vande, “Clinical Pharmacology in Adult and Pediatric Inflammatory Bowel Disease,” Inflammatory Bowel Disease 24, no. 12 (2018): 2527–2542.
1. M. J. Rosen, P. Minar, and A. A. Vinks, “Review Article: Applying Pharmacokinetics to Optimise Dosing of Anti‐TNF Biologics in Acute Severe Ulcerative Colitis,” Alimentary Pharmacology & Therapeutics 41, no. 11 (2015): 1094–1103.
1. D. Turner, A. Ricciuto, A. Lewis, et al., “STRIDE‐II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat‐To‐Target Strategies in IBD,” Gastroenterology 160, no. 5 (2021): 1570–1583.
1. R. J. Colman, T. Mizuno, K. Fukushima, et al., “Real World Population Pharmacokinetic Study in Children and Young Adults With Inflammatory Bowel Disease Discovers Novel Blood and Stool Microbial Predictors of Vedolizumab Clearance,” Alimentary Pharmacology & Therapeutics 57, no. 5 (2023): 524–539.
1. J. S. Hyams, D. Turner, S. A. Cohen, et al., “Pharmacokinetics, Safety and Efficacy of Intravenous Vedolizumab in Paediatric Patients With Ulcerative Colitis or Crohn's Disease: Results From the Phase 2 HUBBLE Study,” Journal of Crohn's & Colitis 16, no. 8 (2022): 1243–1254.